What is Abcore?
Abcore operates at the intersection of advanced molecular biology and therapeutic development, specializing in the creation of antibody and nanobody products. The company has established a robust, end-to-end platform for nanobody and single domain (VHH) antibody discovery, leveraging proprietary phage display libraries to deliver high-affinity reagents. By providing comprehensive discovery and development capabilities alongside custom antibody production, Abcore serves as a critical partner for pharmaceutical and biotech entities seeking to navigate complex protein-based therapeutic pipelines. Its strategic location in San Diego places it at the heart of a global innovation hub, allowing for seamless integration with academic research institutions and commercial drug development partners.
How much funding has Abcore raised?
Abcore has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Abcore
PPP
Public-Private Partnership
What's next for Abcore?
Following this late-stage funding, Abcore is expected to scale its operational capacity to meet the rising demand for specialized VHH antibody solutions. The strategic allocation of this capital will likely focus on expanding the firm's phage display library diversity and enhancing its high-throughput screening infrastructure. As the industry shifts toward more targeted, smaller-molecule biologics, Abcore's focus on nanobody technology positions it to capture significant market share. Future growth will likely involve deepening its service offerings for custom antibody production, thereby solidifying its role as a foundational provider in the global biopharmaceutical supply chain.
See full Abcore company page